The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / MIF Cytokine May Impact Inflammation, Bone Formation in Ankylosing Spondylitis

MIF Cytokine May Impact Inflammation, Bone Formation in Ankylosing Spondylitis

December 18, 2017 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In studies of mice with the HLA-B27 gene, researchers saw the usual clinical signs of AS, but if the mice “are housed in a germ-free condition, no clinical manifestations develop. So an environmental trigger for the development of spondyloarthritis is likely, with the gut being a prime source,” says Dr. Haroon.

You Might Also Like
  • Tracking Bone Deterioration in Patients with Ankylosing Spondylitis
  • New Findings on Rheumatic Drug Therapies among Patients with Ankylosing Spondylitis, Gout, SLE
  • Anti-TNF Agents May Improve Clinical Symptoms of Ankylosing Spondylitis
Explore This Issue
December 2017
Also By This Author
  • Auto-Injectable Methotrexate: New Treatment Option for RA

Intestinal bugs, such as Heliobacter pylori, have been shown to trigger MIF release in past studies, so the researchers suspected “the gut could be where the disease process begins in SpA,” says Dr. Haroon.7 “A gut-related factor could be a clue to onset, severity or certain clinical features of the disease. Fecal and serum calprotectin levels have been used for predicting irritable bowel syndrome presence and activity, but a similar marker for AS has yet to be conclusively proved.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Study

The researchers enrolled 147 AS patients who satisfied the modified New York diagnostic criteria and 61 healthy volunteers used as controls.8 They collected baseline serum samples, annually recorded clinical variables and took radiographs every two years. The AS patients were classified as either progressors or nonprogressors based on the annual rate of increase in their modified Stoke AS Spinal Score (mSASSS), with 56 progressors and 91 nonprogressors. The AS patients stayed on their regular, daily doses of standard therapy: non-steroidal anti-inflammatory drugs (NSAIDs) and/or tumor necrosis factor (TNF) inhibitors.

The researchers also analyzed the patients’ ileal tissue to identify MIF-producing cells in the gut. Using flow cytometry, they identified MIF-producing subsets, expression patterns of the MIF receptor CD74, and MIF-induced TNF production in the patients’ peripheral blood samples. They analyzed MIF-induced mineralization of osteoblast cells, and measured β-catenin levels.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The study’s results show MIF plays important roles in AS disease progression. In the AS patients, MIF serum levels measured higher at baseline compared with levels in healthy controls. This factor independently predicted radiographic disease progression in these patients, says Dr. Haroon.

MIF levels measured higher in their synovial fluid, and MIF expression was elevated in their peripheral joints and ileum tissue, as well. MIF-producing macrophages and Paneth cells were enriched in their guts. MIF also induced TNF production in the AS patients’ monocytes. MIF activated β-catenin in their osteoblasts and promoted osteoblast mineralization, which suggests it possibly stimulates the pathogenic bone growth seen in AS.

AS patients in the study also featured lower levels of the protein CD74 in their monocytes, which could be a sign of disease progression that must be explored further, says Dr. Haroon. CD74 is a high-affinity receptor for MIF. When MIF binds to CD74’s surface, its intracellular domain (ICD) cleaves or splits open.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Spondyloarthritis Tagged With: ACR Journal Review, American College of Rheumatology, Ankylosing Spondylitis, Arthritis & Rheumatology, bone, cytokine, drug, gut, inflammation, inhibitory factor, macrophage migration, MIF, patient care, predict, progression, Research, Rheumatic Disease, spinal fusion, spine, study, therapeutic targetIssue: December 2017

You Might Also Like:
  • Tracking Bone Deterioration in Patients with Ankylosing Spondylitis
  • New Findings on Rheumatic Drug Therapies among Patients with Ankylosing Spondylitis, Gout, SLE
  • Anti-TNF Agents May Improve Clinical Symptoms of Ankylosing Spondylitis
  • Imaging in Ankylosing Spondylitis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.